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COMPARATIVE ANALYSIS: COVID-19 DIVERSITY

Abstract
The purpose of this study was to compare the demographic variables of three populations,
COVID-19 vaccine trial participants, COVID-19 deaths, and individuals vaccinated for COVID19, to determine if the trial participants were appropriately representative. Demographic data
(age, sex, race and ethnicity, and presence of comorbidities) were collected from publicly
available datasets, organized, and compared. The demographic characteristics of the vaccine
clinical trials participants were comparable to those who died due to COVID-19, but less
comparable to those who were the first to receive a COVID-19 emergency-use-authorized
vaccine.
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Introduction
Clinical trials are imperative to determine the safety and efficacy of new drugs, biologics,
and medical devices. Because people of different subgroups may have various responses to
medical treatments, it is crucial to test investigational products in a variety of populations (U.S.
Food & Drug Administration, 2014), and the coronavirus disease 2019 (COVID-19) vaccines are
no exception.
Background
COVID-19, also known as, severe acute respiratory syndrome coronavirus 2 (SARSCoV-2), was first detected in Wuhan, China, in December 2019 (Centers for Disease Control and
Prevention, 2021d). The COVID-19 outbreak quickly spread worldwide. On March 11, 2020,
World Health Organization (WHO) director-general, Dr. Tedros Adhanom Ghebreyesus,
publicly declared COVID-19 a global pandemic. Pharmaceutical companies understandably did
not hesitate and promptly began research on treatments and vaccines for the novel coronavirus.
Due to the urgency that accompanies a pandemic, clinical trials and overall recruitment of
participants were accelerated. This made it possible for the Food and Drug Administration
(FDA) to authorize three COVID-19 vaccines for emergency use quickly.
Pfizer-BioNTech and Moderna were the first two pharmaceutical companies that received
FDA Emergency Use Authorization (EUA) of their mRNA vaccines in December 2020 (U.S.
Food and Drug Administration, 2020a, 2020b). Soon after, Johnson & Johnson/Janssen (J&J)
received FDA EUA for a single-dose vaccine in February 2021 (U.S. Food and Drug
Administration, 2021). Each EUA was based on interim analyses of phase III, multicenter and
international clinical trials, each consisting of thousands of participants (U.S. Food and Drug

COMPARATIVE ANALYSIS: COVID-19 DIVERSITY

Administration, 2020a, 2020b, 2021). As each of these clinical trials are following participants
for two years after vaccine administration, each one has yet to conclude (U.S. Food and Drug
Administration, 2020a, 2020b, 2021).
Although the FDA analyzes the diversity amongst clinical trial participants prior to
authorizing the vaccines for emergency use, certain subgroups may be underrepresented. As a
result, subgroups that are not appropriately represented in the vaccine clinical trials are receiving
one of the three vaccines with the possibility of unknown risks.
Vaccine Distribution Plan
Upon the first EUA of a COVID-19 vaccine, the U.S. COVID-19 vaccination distribution
program was initiated by the Advisory Committee on Immunization Practices (ACIP), as there
was a limited supply (Centers for Disease Control and Prevention, 2021c). During the first phase,
the ACIP prioritized health care personnel and residents and staff members of long-term care
facilities (LTCF; Dooling et al., 2020). The ACIP is a group of medical and public health experts
with the U.S. CDC that develops recommendations and guidance on effective control of vaccinepreventable diseases. As age is known to play a significant role in the severity of COVID-19
infection, the vaccine allocation plan advanced accordingly. In Phase 1b of the vaccine allocation
plan, the vaccine was offered to individuals aged 75 and older and in Phase 1c, to people aged
65-75 years (Centers for Disease Control and Prevention, 2021c). The timeline of vaccine
distribution is presented in Appendix A.
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Adverse Events Targeting Subgroups
Individuals who receive a COVID-19 vaccine and their health care providers are strongly
encouraged to report any adverse events they experience through the Vaccine Adverse Event
Reporting System (VAERS). The purpose of VAERS is to detect possible safety signals by
monitoring adverse events associated with vaccine use. The reports are monitored and reviewed
by the CDC, the FDA, and the U.S. Department of Health & Human Services (HHS). This
information is essential to assess relationships to the vaccines and ultimately determine potential
risks associated. The adverse event (AE) reports described below are a few examples of potential
risks that each seem to affect certain subgroups more than others:
1. Many reports of developing thrombosis with thrombocytopenia syndrome (TTS)
following administration of the J&J vaccine. TTS occurs when a person develops blood
clots (thrombosis) and a low platelet count (thrombocytopenia). The reports are occurring
mostly in women younger than 50 years old (Centers for Disease Control and Prevention,
2021n). These concerning reports caused a temporary pause in administration of the J&J
vaccine on April 13, 2021, only 6 weeks after it was authorized for emergency use. After
further investigation, the use of this vaccine has since resumed, but the CDC now
recommends that women under 50 consider other vaccine options currently available to
avoid this risk (Centers for Disease Control and Prevention, 2021f, 2021n).
2. The CDC and FDA identified multiple reports of developing myocarditis and pericarditis,
an AE that is occurring particularly in male adolescents and young adults, less than 30
years old (Centers for Disease Control and Prevention, 2021n). Most of these cases are
occurring after an mRNA COVID-19 vaccination (Pfizer-BioNtech or Moderna).

3

COMPARATIVE ANALYSIS: COVID-19 DIVERSITY

Ongoing investigations are in progress to assess the relationship (Centers for Disease
Control and Prevention, 2021n).
3. Reports of Guillain-Barre Syndrome (GBS), an overall rare condition, were identified
(Centers for Disease Control and Prevention, 2021n). GBS is a condition in which the
immune system attacks the nerves causing muscle weakness and sometimes paralysis.
The cases have been predominately reported in men, aged 50 years and older,
approximately two weeks after receiving the J&J vaccine.
Although these adverse events are considered rare, each of the AEs are recognizably
occurring amongst certain demographic subgroups (e.g., women, adolescents, men). Therefore,
recruiting and maintaining a diverse study population throughout a clinical trial is crucial to
assess these differences in advance.
Diversity in Clinical Trials
There are many complex sources of racial and ethnic disparities in health care. According
to Nelson (2002), historic and contemporary social and economic inequalities, as well as
persistent racial and ethnic discrimination in many sectors of American life, are just a few
contributing factors. The Nazi experiments and the Tuskegee syphilis study are two historical
cases that may have initiated hesitation amongst minority groups to participate in clinical trials.
When the Tuskegee Study was ruled “ethically unjustified,” an ethical and regulatory framework
quickly began to take shape in the U.S (Centers for Disease Control and Prevention, 2021b).
The Belmont Report (1978), written by the National Commission for the Protection of Human
Subjects of Biomedical and Behavioral Research, identifies basic ethical principles and
guidelines that address the ethical issues, which arise from the conduct of human subjects
research. To overcome health disparities, the National Institutes of Health (NIH) Revitalization
4
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Act of 1993 published guidelines that would enhance the inclusion specifically of women and
minorities in clinical research (National Institutes of Health, 1993). Although the preceding
documents have created a structural, ethical, and moral framework, the main sources of guidance
on the ethical conduct of clinical research were evidently written in response to specific events to
avoid future scandals (Emanuel, 2000).
Unfortunately, patient barriers to trial participation still exist and are commonly reported
as fear, mistrust of the medical community, and the overall burden associated with trial
participation (Schmotzer, 2012). Aside from consciously avoiding participation, other barriers
result in underrepresented minority groups in study populations, as well. Such barriers include
physician reluctance to refer minorities to clinical trials, health illiteracy, and financial barriers,
to name a few (Noah, 2003). Bias, stereotyping, prejudice, and clinical uncertainty on the part of
health care providers may also contribute to these disparities (Nelson, 2002).
Van Spall (2007) demonstrated that women, children, the elderly, and those with
common medical conditions are frequently excluded from randomized controlled trials (RCTs).
In 81.3% of the RCTs that Van Spall analyzed, individuals were excluded from trial participation
due to medical comorbidities alone. As the three COVID-19 vaccines are currently available to
all adults in the U.S. (apart from Pfizer-BioNtech, which is now available to those aged 12 and
older), it is important to understand the possibility that not all demographic characteristics were
adequately represented in the vaccine trial populations (Centers for Disease Control and
Prevention, 2021h). Without adequate data across all demographic characteristics, there is a
possibility that COVID-19 vaccines are being administered to patients who were
underrepresented in the vaccine clinical trials.
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Purpose
The impact of the COVID-19 pandemic is not uniform across subgroups. Specifically,
age, sex, and comorbidity are critical risk factors for mortality of COVID-19 (Qin et al., 2020).
In addition, race and ethnicity are clear predictors of severe COVID-19 infection (Mendy et al.,
2020). The purpose of this research was to examine the demographic characteristics amongst the
participants of the three COVID-19 vaccine clinical trials, which each resulted in an EUA, to
understand if subgroups were appropriately represented.
Research Questions
1. Are the demographic characteristics of the participants in the three COVID-19 vaccine trials
comparable to those who died due to the COVID-19 virus?
2. Are the demographic characteristics of the participants in the three COVID-19 vaccine trials
comparable to the individuals who received a COVID-19 emergency-use-authorized vaccine?
3. Are the demographic characteristics of individuals who received a COVID-19 emergencyuse-authorized vaccine comparable to those who died due to COVID-19?
Hypothesis
The hypothesis is that the demographic characteristics of the population that participated
in the vaccine clinical trials are more comparable to those who died due to COVID-19, rather
than to those who were the first to receive a COVID-19 emergency-use-authorized vaccine.
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Methods
First, all demographic characteristics of the study populations, specifically the safety
population, enrolled in each phase II/III clinical trial, Pfizer-BioNtech (BNT162b2), Moderna
(mRNA-1273-P301), and J&J (VAC31518COV3001), were gathered. The data came from the
FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) briefing
document made available to the public on fda.gov. All three clinical trials were multi-center,
randomized, placebo-controlled, and blinded studies, evaluating the efficacy, safety, and
immunogenicity of a COVID-19 vaccine. Each trial included thousands of participants from
various countries and had different data cutoffs due to the time of EUA request submission.
The VRBPAC briefing document for the Pfizer-BioNtech vaccine contained data from
two clinical trials. One of the trials took place in Germany. Therefore, the other clinical trial
(study number C4591001) was used in this analysis. The clinical trial had a data cutoff of
November 14, 2020, and included participants from the U.S., but also from Argentina, Brazil,
Germany, South Africa, and Turkey. The data cutoff date and the list of participating countries
was found in the Pfizer-BioNtech, FDA VRBPAC briefing document (U.S. Food and Drug
Administration, 2020b, p.12, Table 1).
The Moderna trial, study P301, for safety and efficacy enrolled participants at sites within
the United States and had a data cutoff of November 11, 2020. The participating country and the
data cutoff date was found in the Moderna, FDA VRBPAC briefing document (U.S. Food and
Drug Administration, 2020a, p. 12, section 5.2.1; U.S. Food and Drug Administration, 2020a, p.
21, Table 7).
The J&J trial (study number 3001) for safety and efficacy had a data cutoff of January 22,
2021, and enrolled participants from the U.S., South Africa, and five countries in Latin America.
7
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The list of participating countries and the data cutoff date were found in the J&J VRBPAC
briefing document (U.S. Food and Drug Administration, 2021, p. 20, section 5.2.4; U.S. Food
and Drug Administration, 2021, p. 7, section 1).
Although this comparative analysis focused on individuals in the United States, the data
provided in each VRBPAC briefing document did not separate the study populations by country
when summarizing the demographic characteristics. Therefore, the demographic characteristics
of the study populations included individuals from other countries.
Second, the demographic characteristics of those that died due to COVID-19 were
collected from the CDC COVID Data Tracker, which is provided by the National Center for
Health and Statistics (NCHS; Centers for Disease Control and Prevention, 2021a). The datasets
are comprised of provisional death counts posted by the CDC, which is considered the most
complete and accurate dataset of lives lost due to COVID-19. The provisional death count
datasets are based on death certificates and include age, race, ethnicity, gender, comorbidities,
and place of death. For this comparative analysis, the deaths reported from the start of the
pandemic, January 1, 2020, through June 12, 2021, caused by COVID-19 within the United
States were extracted from each of three datasets. A filter was used to extract the deaths that
occurred within the United States as the EUAs were granted by the FDA for use solely in this
country. The race and ethnicity were extracted from the Provisional COVID-19 Death by HHS
Region, Race and Age dataset (Centers for Disease Control and Prevention, 2021j). The age and
sex were extracted from the COVID-19 Provisional Counts: Weekly Updates by Select
Demographic and Geographic Characteristics dataset (Centers for Disease Control and
Prevention, 2021i). The presence of comorbidities was extracted from the Conditions
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Contributing to COVID-19 Deaths, by State and Age dataset (Centers for Disease Control and
Prevention, 2021n).
Third, the demographic characteristics of individuals who have been fully vaccinated in
the United States were collected from the CDC COVID Data Tracker, as well (Centers for
Disease Control and Prevention, 2021a, 2021e). For this comparative analysis, the dataset for
each demographic (age, sex, race, and ethnicity) was downloaded on July 1, 2021, from the
following website: https://covid.cdc.gov/covid-data-tracker/#vaccination-demographic. Those
fully vaccinated in the United States between the dates of December 14, 2020, and June 30,
2021, were included. This data was collected by the jurisdiction and was reported to the CDC.
The population is comprised of individuals who received a second dose of a two-dose vaccine
(Pfizer-BioNTech or Moderna) or one dose of a single-dose vaccine (J&J).
The following demographic characteristics were compared across all three populations:
age, sex, race, and ethnicity. The term sex, opposed to gender, was used in each VRBPAC
briefing document. Therefore, the term was utilized throughout this comparative analysis. In
addition, comorbidity data was compared across the trial participant population and the COVID19 death population. However, this data was not available for the population of fully vaccinated
individuals. Therefore, this demographic characteristic was descriptively analyzed for discussion
only. Appendix B contains a distinct list of the comorbidities of interest from each of the three
clinical trials, which profoundly overlap.
Not all demographic characteristics were reported for each individual across the three
populations. Therefore, N is equal to the total population and Nr is equal to the total population
that the individual demographic characteristic was reported for. Nr was used to calculate each
proportion (n%).
9
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All data used in this comparative analysis is summary data and is not individually
identifying. There is no interaction of intervention with living individuals, and the data cannot be
linked to identifiable inidividuals (living or dead). This research study does not require direct
recruitment of human subjects, which, in turn, poses no risk to the population under analysis. In
addition, each of the individual sponsors (Pfizer-BioNtech, Moderna, and J&J) submitted their
protocols to an institutional review board (IRB) for an ethical review prior to the commencement
of their clinical trials.
Limitations
It is important to keep in mind that all existing data on COVID-19 (SARS-CoV-2) is
relatively new as it first emerged in December 2019. As each of the three COVID-19 vaccines
were recently authorized for emergency use based on interim analyses, there are a limited
number of publications about the clinical trials, which restricted the research. It is also important
to note that each of the phase III clinical trials have yet to conclude. Therefore, the number of
participants that were reported in the VRBPAC briefing documents will not remain the same
throughout the closeout of the clinical trials. Participant retention is always difficult, but now that
each vaccine is available to the public, it will likely contribute to a rise in subject
discontinuations.
Another limitation is the accuracy of the cause-of-death reporting. According to the
National Center of Health Statistics (NCHS) guidance for certifying deaths due to COVID-19,
When a death is due to COVID-19, it is likely the underlying cause of death (UCOD) and
thus, it should be reported on the lowest line used in Part I of the death certificate.
Ideally, testing for COVID-19 should be conducted, but it is considered acceptable to
10
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report COVID-19 on a death certificate without this confirmation if the circumstances are
compelling within a reasonable degree of certainty. (Centers for Disease Control and
Prevention, 2020b, pp. 2-3)
The possibility for over-reporting is probable in these circumstances. The dataset used for this
comparative analysis may be incomplete due to the lag in time between when the death occurred
and when the death certificate is completed, submitted to NCHS, and processed for reporting
purposes. This delay can range from 1 week to 8 weeks or more (Centers for Disease Control and
Prevention, 2021g).
The vaccination data collected from the CDC also has its limitations. Unfortunately, not
every state and territory reports the demographic characteristics data on the vaccine recipients
due to conflicting laws about demographic data collection. For example, Texas does not report
demographic-specific information, but they do report the total number of people vaccinated in
the state. Therefore, the number of people vaccinated in Texas was removed from N resulting in
a smaller population of individuals fully vaccinated in the U.S. (Centers for Disease Control and
Prevention, 2021g).
Three population groups were formed: (Population I) Vaccine Trial Participants,
(Population II) COVID-19 Deaths, and (Population III) Fully Vaccinated Individuals.
The dataset used for Population II: COVID-19 Deaths was not as concise as it was for
Population I: Vaccine Trial Participants. Population II required more calculations in order to
reach somewhat comparable groups. The Conditions Contributing to COVID-19 Deaths, by State
and Age dataset was comprised of International Classification of Diseases, Tenth Revision (ICD10) codes. The CDC (2020) explains the reasoning for the use of these codes:
11
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The International Classification of Diseases (ICD) is designed to promote international
comparability in the collection, processing, classification, and presentation of mortality
statistics. This includes providing a format for reporting causes of death on the death
certificate. The reported conditions are then translated into medical codes through use of
the classification structure and the selection and modification rules contained in the
applicable revision of the ICD, published by the World Health Organization (WHO).
These coding rules improve the usefulness of mortality statistics by giving preference to
certain categories, by consolidating conditions, and by systematically selecting a single
cause of death from a reported sequence of conditions. The single selected cause for
tabulation is called the underlying cause of death, and the other reported causes are the
non-underlying causes of death. The combination of underlying and non-underlying
causes is the multiple causes of death.
The ≥ 1 comorbidity group was calculated by subtracting individuals that had an ICD 10 code of
at least one of the following: S00-T88, V01-X59, X60-X84, X85-Y09, Y10-Y36, Y40-Y89,
and/or U01-U03 (Intentional and unintentional injury, poisoning, and other adverse events) from
the total number of individuals with an ICD 10 code of U07.1 (COVID-19) and ≥ 1 comorbidity.
The preceding ICD-10 codes are defined in Appendix C.
Analysis
Microsoft Excel (2012) functionality was used to consolidate, organize, calculate, and
graph the demographic characteristics of the three populations. Graphical and numerical
descriptive methods were used to summarize the key demographic characteristics across all
populations.

12
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To answer research Question One --- “Are the demographic characteristics of the
participants in the three COVID-19 vaccine trials representative of deaths due to the COVID-19
virus?” --- the following populations were compared: (Population I) Vaccine Trial Participants
and (Population II) COVID-19 Deaths. The proportion of vaccine trial participants belonging to
each demographic characteristic will be directly compared to the proportion of the same
demographic characteristic in the COVID-19 death population. For example, the proportion of
males in the vaccine trial participant population was compared to the proportion of males that
have died due to COVID-19 and again to those who are fully vaccinated.
To answer Research Question Two --- “Are the demographic characteristics of the
participants in the three COVID-19 vaccine trials representative of individuals who received a
COVID-19 emergency use authorized vaccine?” --- the following populations were compared:
(Population I) Vaccine Trial Participants and (Population III) Fully Vaccinated Individuals. The
proportion of vaccine trial participants belonging to each demographic characteristic was directly
compared to the proportion of the same demographic characteristic for the individuals fully
vaccinated.
To answer Research Question Three --- “Are the demographic characteristics of the
COVID-19 death population representative of individuals who received a COVID-19
emergency-use-authorized vaccine?” --- the following populations were compared: (Population
II) COVID-19 Deaths and (Population III) Fully Vaccinated Individuals. The proportion of the
individuals fully vaccinated belonging to each demographic characteristic was directly compared
to the proportion of the same demographic characteristic for the COVID-19 death population.

13
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To determine if the diversity of the vaccine trial participant population (Population I) is
overall representative of the diversity of COVID-19 deaths (Population II) and/or those that are
fully vaccinated (Population III), a simplified correlation table was employed to test the
hypothesis. The hypothesis is that the demographic characteristics of the population that
participated in the vaccine clinical trials are more representative of those who died due to
COVID-19 rather than those who were first to receive a COVID-19 emergency-use-authorized
vaccine. Each demographic characteristic proportion was compared across the three populations.
The two proportions with the smallest difference were assigned a “1” and the remaining
population was assigned a “0”. After this was complete for each demographic characteristic, the
columns were totaled. The two populations with the highest totals were considered more
comparable to each other.

14
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Results
Three populations and their available demographic characteristics were identified:
•

Population I: Vaccine Trial Participants
o The total safety population in each clinical trial was combined for a total of
114,410 participants.

•

Population II: COVID-19 Deaths
o As of June 16, 2021, a total of 590,091 COVID-19 related deaths were reported
within the United States between January 1, 2020, and June 12, 2021.

•

Population III: Fully Vaccinated Individuals
o From December 14, 2020, through June 30, 2021, a total of 154,884,686
individuals have been fully vaccinated within the United States.
Population I is comprised of demographic characteristics from all three vaccine clinical

trials, depicted in Tables 1-3. The following demographics were included for each population,
sex, age, race, and ethnicity.

15
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Table 1

Demographic Characteristics of the Pfizer-BioNtech Clinical Trial Participants
Demographic Characteristic

Total
Number
Age
≥ 18 to < 65
31416
≥ 65
8613
Sex
Male
20376
Female
19901
Race
American Indian or Alaska Native
253
Asian
1763
Black or African American
3929
Native Hawaiian or other Pacific islander
83
White
33006
Other/Not Reported
227
Multiracial
1016
Ethnicity
Hispanic or Latino
10553
Not Hispanic or Latino
29499
High Risk
≥ 1 comorbidity
18592
Comorbidities
None
21685
Note. Adapted from FDA Briefing Document Pfizer-BioNTech COVID-19 Vaccine (p. 20), by
U.S. Food and Drug Administration, 2020, (https://www.fda.gov/media/144245/download).
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Table 2
Demographic Characteristics of the Moderna Clinical Trial Participants
Demographic Characteristic

Total
Number
Age
≥ 18 to < 65
22830
≥ 65
7520
Sex
Male
15995
Female
14355
Race
American Indian or Alaska Native
230
Asian
1385
Black or African American
3090
Native Hawaiian or other Pacific islander
66
White
24023
Other/Not Reported
636
Multiracial
634
Ethnicity
Hispanic or Latino
6234
Not Hispanic or Latino
23834
High Risk
≥ 1 comorbidity
6742
Comorbidities
None
23608
Note. Adapted from FDA Briefing Document Moderna COVID-19 Vaccine (p. 21), by U.S. Food
and Drug Administration, 2020, (https://www.fda.gov/media/144434/download).
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Table 3
Demographic Characteristics of J&J Clinical Trial Participants
Demographic Characteristic

Total
Number
Age
≥ 18 to < 65
35222
≥ 65
8561
Sex
Male
24053
Female
19722
Race
American Indian or Alaska Native
4143
Asian
1430
Black or African American
8515
Native Hawaiian or other Pacific islander
106
White
25696
Other/Not Reported
623
Multiracial
2449
Ethnicity
Hispanic or Latino
19837
Not Hispanic or Latino
22834
High Risk
≥ 1 comorbidity
17858
Comorbidities
None
25925
Note. Adapted from FDA Briefing Document Janssen Ad26.COV2.S Vaccine for the Prevention
of COVID-19 (p. 22), by U.S. Food and Drug Administration, 2020,
(https://www.fda.gov/media/146217/download).

The presence of at least one comorbidity was captured in each clinical trial as shown in
Tables 1-3. However, comorbidity data for Population III: Fully Vaccinated Individuals is not
available. The total count and proportion of each demographic characteristic across all three
populations is shown in Table 4, where the first column, Population I: Vaccine Trial Participants
is comprised of data from Tables 1-3.

18
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Table 4
Summary of Demographic Characteristics Across All Three Populations

Age

Sex

Race

≥ 18 to < 65
≥ 65

Female
Male

Population I:
Vaccine Trial
Participants
(Na=114,410)
n (%)

Population II:
COVID-19
Deaths
(N=590,091)
n (%)

Population III:
Fully
Vaccinated
(N=154,884,686)
n (%)

Nrb=114,162

Nr=589,769

Nr=136,948,339

89,468 (78.2)
24,694 (21.6)

120,199 (20.4)
469,570 (79.6)

97,048,829 (70.9)
39,899,510 (29.1)

Nr=114,402

Nr=N

Nr=141,675,981

53,978 (47.2)
60,424 (52.8)

266,480 (45.2)
323,611 (54.8)

75,053,468 (47.0)
66,622,513 (53.0)

Nr=113,303

Nr=481,395

Nr=82,494,562

American Indian or Alaska Native
Asian
Black or African American
Native Hawaiian or other Pacific islander
White
Multiracial/ Other/ Unknown
Ethnicity

4,626 (4.0)
4,578 (4.0)
15,534 (13.6)
255 (0.2)
82,725 (72.3)
5,585 (4.9)

6,667 (1.1)
22,616 (3.8)
88,857 (15.1)
1,083 (0.2)
358,263 (60.7)
3,909 (0.8)

899,877 (1.1)
6,031,703 (7.3)
8,541,996 (10.4)
273,413 (0.3)
59,020,327 (71.5)
7,727,246 (9.4)

Nr=112,791

Nr=588,109

Nr=96,587,754

Hispanic or Latino
Not Hispanic or Latino
Comorbidities

36,624 (32.0)
76,167 (66.6)

108,695 (18.4)
479,414 (81.2)

14,093,192 (14.6)
82,494,562 (85.4)

Nr=N

Nr=N

≥ 1 comorbidity
43,192 (37.8) 576,610 (97.7)
None
71,218 (62.2)
13,481 (2.3)
a
N is equal to the total number of individuals in the population
b
Nr is equal to the total number of individuals that reported the demographic characteristics

-

Note. Adapted from Provisional COVID-19 Deaths by HHS Region, Race, and Age, Conditions
Contributing to COVID-19 Deaths, by State and Age, Provisional COVID-19 Deaths by Sex and
Age, Demographic Characteristics of People Receiving COVID-19 Vaccinations in the United
States, by Centers for Disease Control and Prevention, 2021j, 2021m, 2021k, 2021e.

19

COMPARATIVE ANALYSIS: COVID-19 DIVERSITY

Age
The ages used in this analysis were divided into two groups, which each have a sizeable
range. The two ranges used for this comparative analysis were ≥ 18 to < 65 years old and ≥ 65
years old.
Age distribution was similar in Population I: Vaccine Trial Participants and Populations
III: Fully Vaccinated Individuals, but significantly different in Population II: COVID-19 Deaths.
Age was reported for 114,162 individuals in Population I; 589,769 in Population II; and
136,948,339 in Population III (Nr) as shown in Table 4. There was a higher percentage of
individuals in the ≥ 18 to < 65-year-old range in Population I and Population III (78.2% and
70.9%, respectively), than in Population II (20.4%). Population II is made of 79.6% of
individuals aged 65 years or older as shown in Figure 1.
Figure 1

Percent of Reported Population

Distribution of Age Across Populations
90.0%
80.0%

79.6%

78.2%

70.9%

70.0%
60.0%
50.0%
40.0%
30.0%
20.0%

21.6%

29.1%
20.4%

10.0%
0.0%

Population I:
Vaccine Trial
Participants

Population II:
COVID-19 Deaths

Population III: Fully
Vaccinated
Individuals

≥ 18 to < 65

78.2%

20.4%

70.9%

≥ 65

21.6%

79.6%

29.1%
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Sex
The sex of each individual across the three populations was reported as male or female
with the exception of eight participants from the J&J vaccine clinical trial. Of those eight
participants, six were categorized as Undifferentiated and two were categorized as Unknown.
Since only male and female categories were reported for Populations II and III, these eight
participants were removed from the analysis.
Sex was reported for 114,402 trial participants; 590,091 COVID-19 deaths; and
141,675,981 fully vaccinated individuals (Nr) as male or female as shown in Table 4. Overall,
there were slightly more male participants than female participants in both the vaccine trial
participant population (52.8%) and the COVID-19 death population (54.8%). However, there
were slightly fewer male participants in the fully vaccinated population (47%) as shown in
Figure 2.
Figure 2.

Percent of Reported Population

Distribution of Sex Across Populations

60.0%
50.0%

52.8%

54.8%
47.2%

45.2%

47.0%

53.0%

40.0%
30.0%

Male

20.0%

Female

10.0%
0.0%

Male
Female

Population I:
Vaccine Trial
Participants
52.8%

Population II:
COVID-19 Deaths
54.8%

Population III: Fully
Vaccinated
Individuals
47.0%

47.2%

45.2%

53.0%
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Race
Population I: Vaccine Trial Participants and Population II: COVID-19 Deaths used seven
categories to report race: (a) American Indian or Alaska Native, (b) Asian, (c) Black or African
American, (d) Native Hawaiian or other Pacific islander, (e) White, (f) Other/Unknown and (g)
Multiracial. However, the dataset for Population III: Fully Vaccinated Individuals was
comprised of six categories, with the sixth category comprising of other/unknown and
multiracial individuals. Therefore, the other/unknown and multiracial categories were manually
combined across the remaining two populations, resulting in six racial categories across all three
populations.
As shown in Table 4, race was reported for 113,303 individuals in Population I: Vaccine
Trial Participants; 481,395 in Population II: COVID-19 Deaths; and 82,494,562 in Population
III: Fully Vaccinated Individuals (Nr,). White individuals accounted for the highest proportion in
all three populations as shown in Figure 3. However, the proportion of White individuals in
Population II: COVID-19 Deaths is lower (60.7%) than in Populations I & III (72.3% and
71.5%, respectively). Black or African Americans accounted for the second highest proportion in
all three populations. However, opposite from the White population, Blacks or African
Americans had lower proportions in Populations I &III (13.6% and 10.4%) than in Population II
(15.1%). Individuals who were reported as multiracial/other/unknown is low in Population II
(0.8%), but higher in Populations I & III (4.9% and 9.4%, respectively). Figure 3 displays the
proportion of race across all the three populations.
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Figure 3
Distribution of Race Across Populations

Race Across Popualtions
80.0%

Percent of Reported Population (Nr)
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20.0%
10.0%
0.0%
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Native
African Hawaiian or
American
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Pacific
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White

Multiracial/
Other/
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Ethnicity
All three populations were categorized by ethnicity: Hispanic or Latino and Not Hispanic
or Latino. As shown in Table 4, race was reported for 112,791 individuals in Population I:
Vaccine Trial Participants; 588,109 in Population II: COVID-19 Deaths; and 96,587,754 in
Population III: Fully Vaccinated Individuals (Nr,). All three populations include more Not
Hispanic or Latino than Hispanic or Latino individuals. Population I has the highest Hispanic or
Latino proportion (32.5%) as well as the lowest proportion of Not Hispanic or Latino individuals
(66.6%). Figure 4 illustrates the distribution of ethnicity across each of the three populations.
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Figure 4

Percent of Reported Population (Nr)

Distribution of Ethnicity Across Populations
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81.5%
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Comorbidities
Table 5 shows the calculation used to reach the number of individuals that died due to the
COVID-19 virus with one or more comorbidities
Table 5
Population II Comorbidity Calculation
Total Deaths with an ICD-10 code U07.1(COVID-19) and at least one other ICD-10 code (i.e.
comorbidity)c
Total Deaths with an ICD-10 code U07.1 (COVID-19) and at least one of the following: S00T88, V01-X59, X60-X84, X85-Y09, Y10-Y36, Y40-Y89, U01-U03d
Population II: COVID-19 Deaths ≥1 or more comorbidity
c

Appendix A contains a full list of comorbidities reported in conjunction with COVID-19 (ICD-10 code U07.1).
Appendix C contains the corresponding disease for each of the ICD-10 codes removed from the analysis.

d
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Presence of a comorbidity was reported for 114,410 individuals in Population I: Vaccine
Trial Participants and 590,091 in Population II: COVID-19 Deaths as shown in Table 4. Figure 5
shows a significantly higher proportion with one or more comorbidities in the COVID-19 death
population, 97.7%, than in vaccine trial participants, 37.8%.
Figure 5
Distribution of Comorbidities Between Vaccine Trial Participants and COVID-19 Deaths

Percent of Reported Population (Nr)

120.0%
100.0%
80.0%
60.0%
40.0%
20.0%
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Population I: Vaccine Trial Participants

Population II: COVID-19 Deaths

≥ 1 comorbidity

37.8%

97.7%

None

62.2%

2.6%

≥ 1 comorbidity

None
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Overall Comparison
Table 6 was created to compare demographic characteristics individually across all three
populations. Specifically, it shows that the demographic characteristics of the participants in the
three COVID-19 vaccine trials (Population I) are more comparable to those who died due to the
COVID-19 virus (Population II) than to individuals who have been fully vaccinated (Population
III).
1. The demographic characteristics of the participants in the three COVID-19 vaccine trials
(Population I) and to those who died due to the COVID-19 virus (Population II) are
comparable for most demographic characteristic categories. Age is the only demographic
characteristic that is not comparable between these two populations.
2. The demographic characteristics of the participants in the three COVID-19 vaccine trials
(Population I) are somewhat similar to the individuals who received a COVID-19 emergencyuse-authorized vaccine (Population III). Sex, as well as many racial groups, is not comparable
between these two populations.
3. The demographic characteristics of those who died due to the COVID-19 virus (Population II)
is not completely representative of the individuals who were fully vaccinated. Again, racial
groups and age are not comparable between these two populations.
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Table 6
Overall Comparison of Demographic Characteristics Across All Three Populations

Age
Sex
Race

Ethnicity

Population I:
Vaccine Trial
Participants

Population II:
COVID-19
Deaths

Population
III: Fully
Vaccinated

≤ 18 - 64
≤ 65

1
1

0
0

1
1

Male
Female

1c
1

1
1

0
0

American Indian or Alaska Native
Asian
Black or African American
Native Hawaiian or other Pacific
islander
White
Other/Not Reported/multiracial

0
1
1
1

1
1
1
1

1
0
0
0

1
1

0
1

1
0

Hispanic or Latino
0
1
1
Not Hispanic or Latino
0
1
1
TOTAL
9
9
6
c
The two proportions with the smallest difference were assigned a “1” and the
remaining population was assigned a “0”.
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Discussion
The purpose of this study was to compare the demographic variables of three populations,
COVID-19 Vaccine Trial Participants, COVID-19 Deaths, and Individuals Vaccinated for
COVID-19, to determine if the trial participants were appropriately representative. The
demographic characteristics of the vaccine clinical trials participants were comparable to those
who died due to COVID-19, but less comparable to those who were the first to receive a
COVID-19 emergency-use-authorized vaccine.
Age
The age distribution across the three populations differed significantly. The vaccine trial
participant population (Population I) is comparable to the population of individuals fully
vaccinated (Population III). However, Population II: COVID-19 Deaths is entirely inverse of the
other two populations (Populations I & III).
As AE reports seem to be occurring in smaller subgroups (e.g., myocarditis and
pericarditis in individuals under 30 years old, TTS in individuals under 50 years old), organizing
the age data into smaller ranges would be of great value (e.g., ages 16-20, 21-30, 31-40; Centers
for Disease Control and Prevention, 2021n). Due to the predetermined ranges presented in each
VRBPAC briefing document, it was impossible to divide the age ranges further across all three
populations. Of course, this would be possible with the full dataset from each clinical trial and
would be valuable to analyze in future research. Although it is reassuring from a safety
standpoint that the participants included in the vaccine clinical trials represent the age range of
the population fully vaccinated, it is evident that the elder population needs the most aid when it
comes to surviving COVID-19.
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Sex
The results suggest that men and women were equally represented across all three
populations. The slightly higher proportion of women receiving a COVID-19 vaccination first
may be due to the vaccine allocation plan which prioritized healthcare personnel (Dooling, et al.,
2020).
Race & Ethnicity
Population I: Vaccine Trial Participants were overall racially representative of Population
II: COVID-19 Deaths and Population III: Individuals Fully Vaccinated. However, there are a
few obvious outliers. Black or African Americans are the only racial group with a smaller
proportion in Population I and Population III, than in Population II. Although there is a higher
proportion of Blacks and African Americans dying due to the COVID-19 virus, they may not be
as willing to participate in clinical trials or voluntarily receive a vaccination that has yet to be
fully approved. This data may suggest that mistrust in the medical community still exists. In
recent surveys, experience with racial discrimination is a key predictor of COVID-19 vaccine
hesitancy (Savoia et al., 2021). Similarly, Black individuals are less likely to participate in other
vaccine trials (e.g., HIV vaccine trials) due to misinformation, fear and mistrust, and overall
stigma (Moutsiakis & Chin, 2007). With the unfortunate circumstances of racism in clinical trial
history, the medical community has yet to regain trust of Blacks and African Americans.
Native Hawaiians or other Pacific islanders only represent 0.2% of the vaccine trial
participant population (Population I), which translates to a total of only 255(n) participants
spanning all three vaccine trials (Nr = 113,303). Although the proportion closely compares to the
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subgroup in Population III (0.3%), approximately 273,413(n) Native Hawaiians or other Pacific
islanders are fully vaccinated via an EUA vaccine.
Similarly, Asians make up 4% of the vaccine trial participant population (Population I)
which converts to a total 4,578(n) participants spanning all three vaccine trials (Nr = 113,303).
The proportion of individuals in Population III (Nr = 82,494,562) is almost two-fold (7.3%) the
proportion of Asians in Population I. Precisely 6,031,703(n) Asian Americans have been fully
vaccinated via an EUA vaccine. Given that an individual from Population III received a
vaccination from only one of the three authorized vaccines, it may be of value to compare n from
Population III with the average of the total number of Asians in each vaccine clinical trial from
Tables 1-3. Although the proportions (4% and 7.3%) don’t seem like a significant difference, the
total numbers (n) may be more telling.
Although the ethnicity represented in each population was extremely similar, there was a
noticeable trend in Figure 4. As the proportion of Hispanic or Latinos decreased across the three
populations, the proportion of Not Hispanic or Latinos increased.
Comorbidities
As underlying health conditions can play a role in the severity of COVID-19, all three
clinical trials had the intention of including these groups during recruitment. Unfortunately,
during the data collection new limitations surfaced. This data was not available for Population III
and the data available for Population II was not concise. It is common for multiple ICD-10 codes
to be used in death reports to capture both the chain-of-event conditions and significant
contributing conditions. As such, combining or removing certain subcategories based on the
ICD-10 codes in this dataset will result in counting a single death multiple times. The only group
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that seemed reasonable to completely remove from the analysis was the “Intentional and
unintentional injury, poisoning, and other adverse events.” This was done for two reasons: (a)
None of the corresponding ICD-10 codes, S00-T88, V01-X59, X60-X84, X85-Y09, Y10-Y36,
Y40-Y89, U01-U03, are likely to increase the severity of COVID-19, nor are they considered an
underlying medical condition, and (b) The survival of COVID-19 is unknown if the accidental
death due to an external cause did not occur. Corresponding diseases and injuries for the
preceding ICD-10 codes are listed in Appendix C. In the future, it would be valuable to explore
the number of individuals in each comorbidity subset and compare the populations again. For
example, Gundlapalli et al. (2021) reported obesity as one of the least common significant
contributing conditions listed on death certificates (2.7%), but obesity accounted for 28.5% of
participants in the J&J clinical trial and 70% of those with at least one comorbidity. Taking this
into account, the demographic characteristic of one or more comorbidities in the vaccine trial
population (Population I) is not representative of deaths due to the COVID-19 virus (Population
II). Without data about comorbidities in the individuals fully vaccinated, reports made through
VAERS will be the only way to capture potential risks for individuals with specific
comorbidities.
Each clinical trial used in this analysis will continue to follow participants for two years
after receiving the vaccine (U.S. Food and Drug Administration, 2020a, 2020b, 2021). Some
demographic subgroups were underrepresented during the interim analyses. For the groups that
were sufficiently represented in the clinical trials, potential loss of participants to follow-up
could result in more underrepresented groups when it is time for the final analysis.
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Conclusion
The purpose of this study was to compare the demographic variables of three populations,
COVID-19 Vaccine Trial Participants, COVID-19 Deaths, and Individuals Vaccinated for
COVID-19, to determine if the trial participants were appropriately representative. The
demographic characteristics of the vaccine clinical trials participants were comparable to those
who died due to COVID-19, but less comparable to those who were the first to receive a
COVID-19 emergency-use-authorized vaccine.
Each clinical trial used in this analysis will continue to follow participants for two years
after receiving the vaccine (U.S. Food and Drug Administration, 2020a, 2020b, 2021). Some
demographic subgroups were underrepresented during the interim analyses and potential loss of
participants to follow up could result in more underrepresented groups when it is time for the
final analysis.

32

COMPARATIVE ANALYSIS: COVID-19 DIVERSITY

References
Assistant Secretary for Public Affairs. (2021, June 15). COVID-19 vaccine distribution: The
process. US Department of Health and Human Services.gov.
https://www.hhs.gov/coronavirus/covid-19-vaccines/distribution/index.html.
Centers for Disease Control and Prevention. (2020a, February). International classification of
diseases, tenth revision (ICD-10). https://www.cdc.gov/nchs/icd/icd10.htm.
Centers for Disease Control and Prevention. (2020b, April). NVSS - Vital statistics reporting
guidance: Guidance for certifying deaths due to coronavirus disease 2019 (COVID-19).
https://www.cdc.gov/nchs/data/nvss/vsrg/vsrg03-508.pdf.
Centers for Disease Control and Prevention. (2021a). CDC COVID data tracker.
https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/.
Centers for Disease Control and Prevention. (2021b, April 22). Tuskegee study - timeline - CDC
- nchhstp. https://www.cdc.gov/tuskegee/timeline.htm.
Centers for Disease Control and Prevention. (2021c, May 14). How CDC is making Covid-19
vaccine recommendations. https://www.cdc.gov/coronavirus/2019ncov/vaccines/recommendations-process.html.
Centers for Disease Control and Prevention. (2021d, May 24). Basics of covid-19.
https://www.cdc.gov/coronavirus/2019-ncov/your-health/about-covid-19/basics-covid19.html.

33

COMPARATIVE ANALYSIS: COVID-19 DIVERSITY

Centers for Disease Control and Prevention. (2021e, July 1). Demographic characteristics of
people receiving COVID-19 vaccinations in the United States [Data Set].
https://covid.cdc.gov/covid-data-tracker/#vaccination-demographic.
Centers for Disease Control and Prevention. (2021f, July 13). CDC recommends use of Johnson
& Johnson's Janssen COVID-19 vaccine resume. https://www.cdc.gov/coronavirus/2019ncov/vaccines/safety/JJUpdate.html.
Centers for Disease Control and Prevention. (2021g, April 21). Technical notes: Provisional
death counts for Coronavirus Disease (COVID-19).
https://www.cdc.gov/nchs/nvss/vsrr/covid19/tech_notes.htm.
Centers for Disease Control and Prevention. (2021h, May 14). About COVID-19 vaccine
delivered and administration data. https://www.cdc.gov/coronavirus/2019ncov/vaccines/distributing/about-vaccine-data.html.
Centers for Disease Control and Prevention. (2021i, June). COVID-19 provisional counts:
Weekly updates by select demographic and geographic characteristics.
https://www.cdc.gov/nchs/nvss/vsrr/covid_weekly/index.htm.
Centers for Disease Control and Prevention. (2021j, June 12). Provisional COVID-19 deaths by
HHS region, race, and age [Data set]. https://data.cdc.gov/NCHS/Provisional-COVID-19Deaths-by-HHS-Region-Race-and/tpcp-uiv5.

34

COMPARATIVE ANALYSIS: COVID-19 DIVERSITY

Centers for Disease Control and Prevention. (2021k, June 12). Provisional COVID-19 deaths by sex
and age [Data set]. https://data.cdc.gov/NCHS/Provisional-COVID-19-Deaths-by-Sex-andAge/9bhg-hcku.
Centers for Disease Control and Prevention. (2021m, June 13). Conditions contributing to
COVID-19 deaths, by state and age [Data set]. https://data.cdc.gov/NCHS/ConditionsContributing-to-COVID-19-Deaths-by-Stat/hk9y-quqm.
Centers for Disease Control and Prevention. (2021n, July 12). Selected adverse events reported
after COVID-19 vaccination. https://www.cdc.gov/coronavirus/2019ncov/vaccines/safety/adverse-events.html.
Charlson , M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of
classifying prognostic comorbidity in longitudinal studies: development and validation.
Journal of Chronic Diseases, 40(5), 373-83. https://pubmed.ncbi.nlm.nih.gov/3558716/.
Dooling, K., McClung, N., Chamberland, M., Marin, M., Wallace, M., Bell, B.P., Lee, G.M.,
Talbot, K., Romero, J.R., Oliver, S.E. (2020). The Advisory Committee on Immunization
Practices’ interim recommendation for allocating initial supplies of COVID-19 vaccine—
United States, 2020. MMWR Morb Mortal Wkly Rep, 69, 1857–9.
Emanuel, E. J. (2000). What Makes Clinical Research Ethical?. JAMA, 283(20), 2701.
https://doi.org/10.1001/jama.283.20.2701.
Gundlapalli, A.V., Lavery, A.M., Boehmer, T.K., Beach, M.J., Walke, H.T., Sutton, P.D.,
Anderson, R.N. (2021). Death Certificate–Based ICD-10 Diagnosis Codes for COVID-19

35

COMPARATIVE ANALYSIS: COVID-19 DIVERSITY

Mortality Surveillance - United States, January–December 2020. MMWR Morb Mortal
Wkly Rep, 70, 523-527. http://dx.doi.org/10.15585/mmwr.mm7014e2
Moutsiakis, D. L., & Chin, P. N. (2007, March). Why blacks do not take part in HIV vaccine
trials. Journal of the National Medical Association, 99(3), 254-257.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2569631/.
National Commission for the Protection of Human Subjects of Biomedical and Behavioral
Research. (1978). The Belmont report: ethical principles and guidelines for the protection
of human subjects of research. Bethesda, MD.
National Institute of Health. (1993). NIH Revitalization Act: hearing before the Subcommittee on
Health and the Environment of the Committee on Energy and Commerce, House of
Representatives, One Hundred Third Congress, first session, on H.R. 4, a bill to amend the
Public Health Service Act. U.S. G.P.O.
Nelson, A. (2002). Unequal Treatment: Confronting Racial and Ethnic Disparities in Health
Care. Journal of the National Medical Association, 94(8), 666–668.
Noah, B. A. (2003). The participation of underrepresented minorities in clinical
research. American Journal of Law and Medicine, 29(2), 221-45.
Qin, L., Li, X., Shi, J., Yu, M., Wang, K., Tao, Y., Zhou, Y., Zhou, M., Xu, S., Wu, B., Yang, Z.,
Zhang, C., Yue, J., Cheng, C., Liu, X., & Xie, M. (2020, June 19). Gendered effects on
inflammation reaction and outcome of COVID‐19 patients in Wuhan. Wiley Online
Library. https://onlinelibrary.wiley.com/doi/10.1002/jmv.26137.

36

COMPARATIVE ANALYSIS: COVID-19 DIVERSITY

Savoia, E., Piltch-Loeb, R., Goldberg, B., Miller-Idriss, C., Hughes, B., Montrond, A., Kayyem,
J., & Testa, M. A. (2021, July 9). Predictors of COVID-19 vaccine hesitancy: Sociodemographics, co-morbidity, and past experience of racial discrimination. MDPI.
https://www.mdpi.com/2076-393X/9/7/767/htm.
Schmotzer, G. L. (2012). Barriers and facilitators to participation of minorities in clinical trials.
Ethnicity & Disease, 22 (2), 226-230.
https://ethndis.org/edonline/index.php/ethndis/article/view/510/562.
U.S. Centers for Medicare and Medicaid Services. (2020, December). 2021 ICD-10. CMS.
https://www.cms.gov/medicare/icd-10/2021-icd-10-pcs.
U.S. Food and Drug Administration. (2014, September 12). Basics about clinical trials.
https://www.fda.gov/patients/clinical-trials-what-patients-need-know/basics-about-clinicaltrials.
U.S. Food and Drug Administration. (2020a). FDA briefing document Moderna COVID-19
vaccine. https://www.fda.gov/media/144434/download.
U.S. Food and Drug Administration. (2020b). FDA briefing document Pfizer-BioNTech COVID19 vaccine. https://www.fda.gov/media/144245/download.
U.S. Food and Drug Administration. (2021). FDA briefing document Janssen Ad26.COV2.S
vaccine for the prevention of COVID-19. https://www.fda.gov/media/146217/download.

37

COMPARATIVE ANALYSIS: COVID-19 DIVERSITY

Van Spall, H. G., Toren, A., Kiss, A., & Fowler, R. A. (2007). Eligibility criteria of randomized
controlled trials published in high-impact general medical journals. JAMA, 297(11), 1233.
https://doi.org/10.1001/jama.297.11.1233.

38

COMPARATIVE ANALYSIS: COVID-19 DIVERSITY

APPENDICES

39

COMPARATIVE ANALYSIS: COVID-19 DIVERSITY

Appendix A: Timeline of Vaccine Distribution

December 11,
2020

December 13,
2020

December 14,
2020

December 18,
2020

December 20,
2020

February 27,
2021

March 2,
2021

March 17,
2021

April 19,
2021

May 10,
2021

• FDA issued the first EUA for use of the Pfizer-BioNTech COVID-19 vaccine in persons
aged 16 years and older for prevention of COVID-19.

• ACIP prioritized vaccination of health care personnel and residents and staff members of
LTCFs.

• The first deliveries of COVID-19 vaccines began.

• FDA issued the second EUA for use of the Moderna COVID-19 vaccine in persons aged
18 years and older for prevention of COVID-19.

• ACIP published their recommendation for use of the Moderna COVID-19 vaccine.

• FDA issued the third EUA for use of the J&J COVID-19 vaccine in persons aged 18
years and older for prevention of COVID-19.

• Acting HHS Secretary directed that teachers, school staff, and child care workers are
eligible for COVID-19 vaccinations.

• Acting HHS Secretary issued a directive to expand COVID-19 vaccine eligibility to all
Americans by May 1, 2021

• White House COVID-19 Response Team announced that all people age 16 and older are
eligible for the COVID-19 vaccine.

• FDA ameded the EUA for the Pfizer-BioNTech COVID-19 vaccine to include
adolescents 12 through 15 years of age.

Note. Adapted from COVID-19 vaccine distribution: The process, by Assistant Secretary for
Public Affairs, 2021, (https://www.hhs.gov/coronavirus/covid-19vaccines/distribution/index.html).
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Appendix B: List of Comorbidities
Each clinical trial incorporated participants with comorbidities in their safety population.
Below is the list of comorbidities considered in each trial, as well as the list included in the
COVID-19 death population (Population 2).
J&J (VAC31518COV3001)
Comorbidities associated with an increased risk of progression to severe COVID-19.
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Asthma
Cancer
Cerebrovascular disease
Cystic fibrosis
Chronic kidney disease
COPD
Serious heart conditions
Human Immunodeficiency Virus (HIV) infection
Hypertension
Immunocompromised state (blood/organ txp)
Liver disease
Neurologic conditions
Obesity
Pulmonary fibrosis
Sickle cell disease
Type 1 diabetes mellitus
Type 2 diabetes mellitus
Thalassemia
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Moderna (mRNA-1273-P301)
Presence of one or more of the following comorbidities was used to label a participant as high
risk:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Chronic lung disease
Emphysema and chronic bronchitis,
Idiopathic pulmonary fibrosis
Cystic fibrosis
Asthma (moderate- severe)
Significant cardiac disease
Heart failure
Coronary artery disease
Congenital heart disease
Cardiomyopathies
Pulmonary hypertension
Severe obesity (body mass index ≥40 kg/m2)
Diabetes (Type 1, Type 2 or gestational)
Liver disease
Human Immunodeficiency Virus (HIV) infection
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Pfizer-BioNtech (C4591001)
The number of participants who have at least 1 comorbidity that increases the risk of
severe COVID-19 disease: defined at patients who had at least one of the Charlson comorbidity
index category or obesity only (BMI ≥ 30 km/m2).
Charlson Comorbidity Index which is based on a list of 19 conditions identified from
diagnosis in hospital and physician data. Each condition is assigned a weight from 1 to 6. The
index score is the sum of the weights for all identified conditions (Charlson et al., 1987). An
index score of 0 indicates no comorbid conditions, while higher scores indicate a great level of
comorbidity.
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Cancer
Metastatic Carcinoma
Chronic Pulmonary Disease
Congestive Heart Failure
Cerebrovascular Disease
Dementia
Renal Disease
Peripheral Vascular Disease
Myocardial Infarction
Paraplegia and Hemiplegia
Connective Tissue Disease- Rheumatic Disease
Peptic Ulcer Disease
Diabetes without Complications
Diabetes with Complications
Mild, Moderate, or Severe Liver Disease
HIV/AIDS
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COVID-19 Mortality
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Influenza and pneumonia
Chronic lower respiratory diseases
Adult respiratory distress syndrome
Respiratory failure
Respiratory arrest
Other diseases of the respiratory system
Hypertensive diseases
Ischemic heart disease
Cardiac arrest
Cardiac arrhythmia
Heart failure
Cerebrovascular diseases
Other diseases of the circulatory system
Sepsis
Malignant neoplasms
Diabetes
Obesity
Alzheimer disease
Vascular and unspecified dementia
Renal failure
Intentional and unintentional injury, poisoning, and other adverse events
All other conditions and causes (residual)
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Appendix C: ICD-10 Codes and Corresponding Diseases and Injuries
Table 7
ICD-10 Codes Referenced Within
S00-T88
U01-U02
U03
U07.1
V01-Y89

Injury, poisoning and certain other consequences of external causes
Terrorism or Sequelae of terrorism
Unintentional self-harm (suicide)
COVID-19
External causes of morbidity

Note. Adapted from 2021 ICD-10, by U.S. Centers for Medicare and Medicaid Services. 2020,
(https://www.cms.gov/medicare/icd-10/2021-icd-10-pcs).
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Appendix D: List of Abbreviations

ACIP
ASPA
AE
AIDS
CDC
EUA
FDA
HHS
HIV
ICD-10
LTCF
NCHS
NIH
SAE
SARS-CoV-2
TTS
VAERS
VRBPAC
WHO

Advisory Committee on Immunization Practices
Assistant Secretary for Public Affairs
adverse event
acquired immunodeficiency syndrome
Center for Disease Control and Prevention
Emergency Use Authorization
Food and Drug Administration
Health and Human Services
Human Immunodeficiency Virus
International Classification of Diseases
Long-Term Care Facility
National Center for Health Statistics
National Institute of Health
serious adverse event
severe acute respiratory syndrome coronavirus 2
thrombosis with thrombocytopenia syndrome
Vaccine Adverse Event Reporting System
Vaccines and Related Biological Products Advisory Committee
World Health Organization
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